GlassScriptPhysician profile
Gina Keller
NPI 1205250487
$9,027.42
in general payments reported to CMS, 2019-2025
47 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,214 · 2022: $3,330 · 2023: $2,012 · 2024: $236 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,355.33 | 2021-2023 | |
| Viiv Healthcare Company | $1,320.93 | 2021-2025 | Apretude, Rukobia, Dovato |
| Abbvie INC. | $930.92 | 2021-2025 | |
| Janssen Biotech, INC. | $691.28 | 2021-2023 | Symtuza |
| Novo Nordisk INC | $592.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $494.98 | 2021-2023 | Delstrigo, Pifeltro, Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $314.75 | 2021-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $226.37 | 2021 | |
| Amgen INC. | $222.18 | 2021-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $192.35 | 2022-2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.01 | 2021-2023 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $170.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $155.94 | 2021-2023 | Farxiga |
| Antares Pharma, INC. | $154.74 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $154.12 | 2022-2023 | Austedo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.